Last updated: 2026-09-11 08:15:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Insight Molecular Diagnostics Inc. (IMDX) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $3.98, with a market capitalisation of $134.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.42 to $8.51. This page covers its latest market performance, valuation, price trends and company information.
$134.17M | |
$4.04 | |
$8.51 | |
$2.33 | |
$4.10 | |
117.67K | |
206.60K | |
-- | |
$8.51 | |
$2.42 | |
-- | |
-- |
Insight Molecular Diagnostics Inc. (IMDX) is trading at $3.99 in pre-market trading as of 2026-09-10 23:31:00, down 2.78% ($0.11) from the previous close of $4.10
Pre-market trading shows how investors are pricing IMDX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Insight Molecular Diagnostics Inc. (IMDX) moved from $3.84 to $3.98, representing a gain of 3.70% ($0.14).
The stock traded between $3.71 and $4.32 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 174.48 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 25.6%
IMDX is currently trading at $3.98, placing it 25.6% of the way from its 52-week low of $2.42 to its 52-week high of $8.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 58 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Insight Molecular Diagnostics Inc. (IMDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.